AULIN SHERRY
Known title: Chief Financial OfficerCIK: 0001862144
Associated companies
Transaction History
| XENE | ▲ Buy | Option Exercise | 9,334 | $88K | 12/18/2024 | View on chart |
| XENE | ▼ Sell | Tax Withholding | 2,135 | $88K | 12/18/2024 | View on chart |
| XENE | ▼ Sell | Open Market | 7,199 | $297K | 12/18/2024 | View on chart |
| XENE | ▲ Buy | Option Exercise | 16,000 | $185K | 12/18/2024 | View on chart |
| XENE | ▼ Sell | Tax Withholding | 4,490 | $185K | 12/18/2024 | View on chart |
| XENE | ▼ Sell | Open Market | 11,510 | $474K | 12/18/2024 | View on chart |
| XENE | ▲ Buy | Option Exercise | 813 | $7K | 9/2/2022 | View on chart |
| XENE | ▲ Buy | Option Exercise | 2,292 | $7K | 9/2/2022 | View on chart |
| XENE | ▲ Buy | Option Exercise | 6,511 | $31K | 9/2/2022 | View on chart |
| XENE | ▼ Sell | Tax Withholding | 3,293 | $130K | 9/2/2022 | View on chart |
| XENE | ▼ Sell | Open Market | 15,355 | $608K | 9/2/2022 | View on chart |
| XENE | ▲ Buy | Option Exercise | 9,000 | $85K | 9/2/2022 | View on chart |
| XENE | ▲ Buy | Option Exercise | 32 | $240 | 9/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Xenon (XENE) sees insider buying and new analyst price target
Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).
Xenon (XENE) sees insider buying and new analyst price target. Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).